Improving diagnostic and treatment options for Small Cell Lung Cancer

Catherinn

What?

Catherinn BV (Cancer Therapeutics and Innovation) is a virtual research and development company devoted to the improvement of diagnostic and treatment options for Small Cell Lung Cancer (SCLC) patients. Catherinn was started by a group of highly motivated experts and entrepreneurs in the life science and vaccine industry. Important work on SCLC diagnostics and therapy was carried out and patented by the group of prof. Frans Ramaekers, department of molecular cell biology of the Maastricht University Medical Center. We are committed to improving the lives of SCLC cancer patients, both by prevention through early screening and by cure through immunotherapy.

Why?

Small Cell Lung Cancer (SCLC) represents 10% to 15% of clinical lung cancer cases. It is an aggressive malignancy strongly associated with smoking, annually killing an estimated 250,000 people worldwide. SCLC is decreasing in industrialized countries due to smoking cessation programs, but it is increasing in low- and middle-income countries.

In about two thirds of the cases SCLC is detected when metastatic lesions are already present. In those cases patients respond well to a first round of chemotherapy, but then invariably resistance to chemotherapy develops and the fast growth rate of resistant tumor cells will lead to death within a year from the initial diagnosis. Over the last decades survival rates for SCLC have not improved.

Therefore, there is a strong medical need for early screening methods and improved therapy.

Who?

Management team
Ir. Thijs Veerman
Chief Executive Officer:
Ir. Thijs Veerman
Former General Director Netherlands Vaccine Institute
LinkedIn
Poonam Sharma
Director Business Development
Poonam Sharma
Life sciences business consultant
LinkedIn
Prof. Dr. Ben van der Zeijst
Chief Scientific Officer:
Prof. Dr. Ben van der Zeijst
Emeritus professor Vaccines and Vaccination at Leiden University Medical Center
LinkedIn
Pierre Daemen
Chief Financial Officer:
Pierre Daemen
RA Former CFO life science start-ups
LinkedIn
Board members
Dr. Jan van den Brand
Chief Business Development Officer:
Dr. Jan van den Brand
Former General Manager Amgen Netherlands
LinkedIn
Jerry Boot
Chief Marketing Officer:
Jerry Boot
Investor and owner marketing company Booster
LinkedIn

How?

The Neural Cell Adhesion Molecule (NCAM) is a glycoprotein expressed as 120, 140 and/or 180 kDa isoforms, all derived through alternative splicing of a single gene. NCAM 120 contains no intracellular domain, whereas NCAM 140 and 180 have different intracellular domains determined by alternative splicing of exon 18.

We found that NCAM180 is expressed in neuroendrocrine cancer cells (of which SCLC is the major cancer type) and not in other cells, including those of healthy individuals.

This implies that NCAM exon 18 is a biomarker for Small Cell Lung Cancer diagnosis and therapy, where E18 is a Tumor Associated Antigen Specific for SCLC and other Neuroendocrine tumors.

We are looking for collaboration partners for codevelopment to bring our unique and patented NCAM exon 18 approach further. Below you will find diagnostic and treatment options. We would be happy to explore these options with you to make our technology available for your product to improve the lives of the SCLC patients.

Liquied biopsy test for SCLC detection and monitoring

Development of liquid biopsy diagnostic test based on extracellular vesicles (EV) followed by detection of specific SCLC biomarker

  • Screening of (ex-) heavy smokers to detect SCLC in an early stage>> improved survival
  • Monitoring patients during chemotherapy and after chemotherapy for relapses to guide treatment>> more effective treatment (Companion diagnostics)
Liquied biopsy test for SCLC detection and monitoring Liquied biopsy test for SCLC detection and monitoring
Liquied biopsy test for SCLC detection and monitoring

Development of immunotherapy using specific biomarker incorporated onto the proven DC-based immunotherapeutic platform

  • Our primary strategy: Immunization with dendritic cells loaded with E18 nucleic acids or peptides
  • Alternatives: Prime/boost vaccination regimens (check point inhibitor) utilizing E18 biomarker sequences in other platforms or CAR-T treatment utilizing E18 biomarker coding sequences
Immunotherapy for treatment after inititial chemotherapy

Collaboration

Licensing or collaboration opportunities

We are looking for the collaboration or licensing partners who would be interested in developing and commercializing our proven concept further to a diagnostics test for SCLC patients. We are open to idea sharing and future licensing possibilities with respect to the development of SCLC immunotherapy using specific biomarker.

Contact us by mail: thijs@catherinn.com or poonam@catherinn.com and we are happy to provide you with more information.

Contact

Please don't hesitate to contact us if you have a question.

 
#